No Data
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals Insider Ups Holding By 1,515,200% During Year
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
GLP-1 Spillover, AI Empowerment... Could Biopharmaceuticals Become the 'Alternative' to Tech Stocks in 2026?
Citi noted that the indications for GLP-1 are expanding from weight management to cardiovascular and nervous system applications, alongside an anticipated expansion of Medicare coverage and the launch of Eli Lilly and Co’s oral medication orforglipron; AI is fully delivering cost and efficiency gains across R&D, production, and clinical stages; in addition, the DTP (Direct-to-Patient) model is reshaping distribution channels. As a result, the industry’s overall profitability and innovation conversion efficiency are significantly improving.
ADRs End Lower; Token Cat Ltd. Declines 22%
ADRs Close Lower; Biodexa Pharmaceuticals PLC Declines 54%